Session Chair Profile
Associate Professor in the Department of Bioengineering and Therapeutic Sciences at UCSF; Member of the California Institute for Quantitative Biosciences (QB3)
Michael Fischbach is a recipient of the NIH Director’s New Innovator Award, a Fellowship for Science and Engineering from the David and Lucille Packard Foundation, a Medical Research Award from the W.M. Keck Foundation, a Burroughs Wellcome Fund Investigators in the Pathogenesis of Infectious Disease award, a Glenn Award for Research in Biological Mechanisms of Aging, and the Young Investigator Grant for Probiotics Research from the Global Probiotics Council. His laboratory uses a combination of genomics and chemistry to identify and characterize small molecules from microbes, with an emphasis on the human microbiome. Fischbach received his Ph.D. as a John and Fannie Hertz Foundation Fellow in chemistry from Harvard in 2007, where he studied the role of iron acquisition in bacterial pathogenesis and the biosynthesis of antibiotics. Before coming to UCSF, he spent two years as an independent fellow at Massachusetts General Hospital coordinating a collaborative effort based at the Broad Institute to develop genomics-based approaches to the discovery of small molecules from microbes. Fischbach is a member of the board of directors of Achaogen and the scientific advisory boards of NGM Biopharmaceuticals and Indigo Agriculture, and is a co-founder of Revolution Medicines.
Session Abstract – PMWC 2017 Silicon Valley
Session Synopsis: We will explore the latest developments in the human microbiome, including efforts to discover the molecular mediators of microbe-host interactions; the role of diet; the future of fecal microbiota transplant; and emerging themes for the coming second wave of microbiome-oriented companies.